184 related articles for article (PubMed ID: 12497090)
1. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design.
Klein EA; Thompson IM; Lippman SM; Goodman PJ; Albanes D; Taylor PR; Coltman C
Prostate Cancer Prostatic Dis; 2000 Nov; 3(3):145-151. PubMed ID: 12497090
[TBL] [Abstract][Full Text] [Related]
2. A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Dunn BK; Richmond ES; Minasian LM; Ryan AM; Ford LG
Nutr Cancer; 2010; 62(7):896-918. PubMed ID: 20924966
[TBL] [Abstract][Full Text] [Related]
3. Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial.
Pak RW; Lanteri VJ; Scheuch JR; Sawczuk IS
Integr Cancer Ther; 2002 Dec; 1(4):338-44. PubMed ID: 14664728
[TBL] [Abstract][Full Text] [Related]
4. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
5. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.
Peters U; Littman AJ; Kristal AR; Patterson RE; Potter JD; White E
Cancer Causes Control; 2008 Feb; 19(1):75-87. PubMed ID: 17943452
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.
Kim J; Sun P; Lam YW; Troncoso P; Sabichi AL; Babaian RJ; Pisters LL; Pettaway CA; Wood CG; Lippman SM; McDonnell TJ; Lieberman R; Logothetis C; Ho SM
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1697-702. PubMed ID: 16030104
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines.
Venkateswaran V; Fleshner NE; Klotz LH
Prostate Cancer Prostatic Dis; 2004; 7(1):54-6. PubMed ID: 14745439
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of prostate cancer.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Klein EA
J Urol; 2009 Aug; 182(2):499-507; discussion 508. PubMed ID: 19524966
[TBL] [Abstract][Full Text] [Related]
9. Phase III prostate cancer prevention trials: are the costs justified?
Thompson IM; Tangen CM; Klein EA; Lippman SM
J Clin Oncol; 2005 Nov; 23(32):8161-4. PubMed ID: 16278467
[TBL] [Abstract][Full Text] [Related]
10. The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial.
Hernáandez J; Syed S; Weiss G; Fernandes G; von Merveldt D; Troyer DA; Basler JW; Thompson IM
J Urol; 2005 Aug; 174(2):519-22. PubMed ID: 16006884
[TBL] [Abstract][Full Text] [Related]
11. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study.
van den Brandt PA; Zeegers MP; Bode P; Goldbohm RA
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):866-71. PubMed ID: 14504196
[TBL] [Abstract][Full Text] [Related]
12. The selenium and vitamin E cancer prevention trial.
Klein EA; Lippman SM; Thompson IM; Goodman PJ; Albanes D; Taylor PR; Coltman C
World J Urol; 2003 May; 21(1):21-7. PubMed ID: 12756490
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model.
Waters DJ; Shen S; Glickman LT; Cooley DM; Bostwick DG; Qian J; Combs GF; Morris JS
Carcinogenesis; 2005 Jul; 26(7):1256-62. PubMed ID: 15817614
[TBL] [Abstract][Full Text] [Related]
14. Can prostate cancer be prevented?
Klein EA
Nat Clin Pract Urol; 2005 Jan; 2(1):24-31. PubMed ID: 16474573
[TBL] [Abstract][Full Text] [Related]
15. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E supplements and risk of prostate cancer in U.S. men.
Rodriguez C; Jacobs EJ; Mondul AM; Calle EE; McCullough ML; Thun MJ
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):378-82. PubMed ID: 15006912
[TBL] [Abstract][Full Text] [Related]
17. Minority issues in prostate disease.
French DB; Jones LA
Med Clin North Am; 2005 Jul; 89(4):805-16. PubMed ID: 15925651
[TBL] [Abstract][Full Text] [Related]
18. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
19. Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention.
Dunn BK; Ryan A; Ford LG
Recent Results Cancer Res; 2009; 181():183-93. PubMed ID: 19213568
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
